SOX4-mediated FBW7 transcriptional upregulation confers Tamoxifen resistance in ER+ breast cancers via GATA3 downregulation

• Published in: Life sciences (1973) 2022-08, Vol.303, p.120682-120682, Article 120682
• Main Authors: Sharma, Akshay, Thacker, Gatha, Mishra, Mukul, Singh, Anil Kumar, Upadhyay, Vishal, Sanyal, Sabyasachi, Trivedi, Arun Kumar
• Format: Article
• Language: English
• Subjects: ER+ breast cancer; FBW7; GATA3; SOX4; Tamoxifen
• ISSN: 0024-3205; 1879-0631
• DOI: 10.1016/j.lfs.2022.120682

Tamoxifen-mediated endocrine therapy has been standard treatment for ER+ breast cancers; however, majority of them acquire resistance leading to disease relapse. Although numerous substrates of E3 ligase FBW7 are known, only a handful of factors that regulate FBW7 expression and function are reported. In particular, there remains a lack of in-depth understanding of FBW7 transcriptional regulation. Luciferase reporter assay was performed after cloning full length and truncated FBW7 promoters followed by Chromatin immunoprecipitation assay to validate binding of SOX4 on FBW7 promoter. Transcriptional regulation of FBW7 by SOX4 and their biological consequences with respect to ER+ breast cancer was then evaluated using immunoblotting and other cell based assays. SOX4 positively regulates FBW7 at transcriptional level by binding to three putative SOX4 biding sites within 3.1 kb long FBW7 promoter. Analysis of publicly available RNAseq datasets also showed a positive correlation between SOX4 and FBW7 mRNA in cancer cell lines and patient samples. qPCR and Immunoblotting confirmed that transiently or stably expressed SOX4 induced both endogenous FBW7 mRNA and protein levels. Our findings further demonstrated that increased levels of SOX4 and FBW7 in MCF7 mammospheres promoted cancer stemness and tumor cell dormancy. We further showed that both MCF7 mammospheres and MCFTAMR cells had elevated SOX4 levels which apparently enhanced FBW7 to potentiate GATA3 degradation leading to enhanced stemness, tumor dormancy and Tamoxifen resistance in MCF7TAMR as well as patients with ER+ breast cancers. Targeting SOX4-FBW7-GATA3 axis may overcome tamoxifen resistance in ER+ breast cancers. Graphical model depicts that SOX4 positively regulates FBW7 levels in ER+ breast cancers where it promotes stemness, tumor dormancy and TAM resistance by targeting GATA3 and c-Myc. [Display omitted]